Compare LII & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LII | VTRS |
|---|---|---|
| Founded | 1895 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 17.2B |
| IPO Year | 1999 | 2019 |
| Metric | LII | VTRS |
|---|---|---|
| Price | $518.44 | $13.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $569.45 | $13.50 |
| AVG Volume (30 Days) | 388.5K | ★ 7.6M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 1.03% | ★ 3.56% |
| EPS Growth | ★ 1.11 | N/A |
| EPS | ★ 22.79 | N/A |
| Revenue | $5,195,300,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $6.90 | $4.41 |
| Revenue Next Year | $5.73 | $1.96 |
| P/E Ratio | $22.23 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $434.06 | $7.34 |
| 52 Week High | $689.44 | $16.47 |
| Indicator | LII | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 51.68 |
| Support Level | $510.23 | $12.90 |
| Resistance Level | $532.29 | $16.38 |
| Average True Range (ATR) | 17.72 | 0.31 |
| MACD | 8.39 | 0.08 |
| Stochastic Oscillator | 98.01 | 97.35 |
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.